Leqembi (Lecanemab) in Early Alzheimer's Disease: A Review of Clinical Trial Evidence and Therapeutic Implications - PubMed

6 hours ago

Lecanemab (Leqembi) is the first FDA-approved drug targeting amyloid plaques to slow Alzheimer's progression.
The Clarity AD study showed a 27% reduction in cognitive decline in patients with mild cognitive impairment or mild dementia.
Treatment resulted in amyloid-related imaging abnormalities in about 21% of patients, especially in homozygous APOE4 carriers.
Pre-treatment screening for amyloid pathology and APOE4 status is crucial for safety.
Barriers include high financial costs and the need for intravenous administration in healthcare facilities.
Future research should focus on combination therapies to enhance outcomes and improve accessibility.

Hasty Briefsbeta